Clinical trials: asthma
Asthma
Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects
The purpose of the study is to investigate the clinical effects of multiple (28 day) twice-daily doses of OC000459 in comparison to placebo on clinic lung function (FEV1) in mild to moderate asthmatics with an FEV1 of 60-80% of…
- Trial name
- NCT01057927
- Testing
- OC000459
- Where
- 16 sites in Russia
- Volunteers
- 132 people
- Sponsor
- Oxagen Ltd
Asthma
Multicentre Post-market Study of Ectoin® Inhalation Solution in Treatment of Asthma.
The goal of this multi-centre, prospective, open-label, single-arm, post-market clinical follow-up study is to further strengthen the already existing clinical evidence for supportive treatment and symptoms alleviation in asthma…
- Trial name
- EIL-AST (NCT05699941)
- Testing
- Ectoin® Inhalation Solution
- Where
- 5 sites in Poland
- Volunteers
- 204 people
- Sponsor
- Bitop AG
Asthma
FASENRA SCEI for Long-term Use
The purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.
- Trial name
- NCT03588546
- Where
- 29 sites in Japan
- Volunteers
- 653 people
- Sponsor
- AstraZeneca
Asthma, Airway Inflammation
Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) formulation…
- Trial name
- NCT00635882
- Testing
- mometasone furoate/formoterol 100/10 mcg, mometasone furoate/formoterol 200/10 mcg, mometasone furoate/formoterol 400/10 mcg
- Volunteers
- 93 people
- Sponsor
- Organon and Co
Asthma
A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.
The purpose of this study is to demonstrate that the CHF 1535 (fixed combination of Beclometasone Dipropionate (BDP) 100 µg / Formoterol Fumarate (FF) 6 µg) delivered via the NEXT Dry Powder Inhaler (DPI) does not show a greater…
- Trial name
- ADONE (NCT01191424)
- Testing
- CHF1535 NEXT DPI, BDP DPI and formoterol DPI
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Adjuvant Therapy for Severe Asthma by an Oxyhydrogen Generator With Nebulizer
The purpose for the trial is intended to evaluate safety and effectiveness of an oxyhydrogen generator with nebulizer in an adjuvant therapy for patients with severe asthma.
- Trial name
- NCT02883582
- Testing
- oxyhydrogen, oxygen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Asclepius Meditec Inc.
Asthma
Long Term Special Drug Use Investigation of Mepolizumab
This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC).
- Trial name
- NCT03028480
- Testing
- NUCALA Injection
- Volunteers
- 1,061 people
- Sponsor
- GlaxoSmithKline
Asthma
RISA Extension Study - Long Term Safety
The primary purpose of this study is to gather additional safety data for the subjects treated with the Alair System (hereinafter, "Alair-Treated Subjects") who previously completed the one-year study entitled: "Multicenter…
- Trial name
- NCT00401986
- Testing
- Bronchial thermoplasty with the Alair System
- Where
- 8 sites in Brazil, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- Boston Scientific Corporation
Asthma and Rhinitis
Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958
This study will evaluate the duration of effect of GSK2245035 on allergic reactivity by repeating a nasal allergen challenge (NAC) approximately one year after treatment in subjects from TL7116958.
- Trial name
- NCT02446613
- Testing
- Pollen allergen extract
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Asthma
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests.
- Trial name
- NCT00296491
- Testing
- fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP)
- Where
- 121 sites in United States, Canada and 2 more
- Volunteers
- 725 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of CM512 Injection in Subjects With Moderate-to-severe Asthma
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with…
- Trial name
- NCT07011524
- Testing
- CM512 injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Keymed Biosciences Co.Ltd
Allergy
Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus
Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. Many factors such as the biovariability, differences in extraction process and subsequent handling of…
- Trial name
- NCT01147159
- Testing
- Extracts of allergens
- Where
- Switzerland
- Volunteers
- 68 people
- Sponsor
- Roxall Medicina España S.A
Asthma
Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
For the prophylactic treatment of asthma, FP inhaled aerosol (Flixotide ®) administered via a pressurized metered-dose inhaler (pMDI) was approved in China in adults, adolescents older than 16 years of age and children aged 4 to…
- Trial name
- NCT03273946
- Testing
- Fluticasone propionate
- Where
- 4 sites in China
- Volunteers
- 158 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.
The study will investigate the Pharmacokinetic (PK), Pharmacodynamic (PD), the safety and tolerability of AZD4604, as well as to examine the effect of Fractional exhaled Nitric Oxide (FeNO) following the administration of the…
- Trial name
- NCT06732882
- Testing
- AZD4604, Genuair, Turbuhaler
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Asthma
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done during the study.
- Trial name
- NCT00102882
- Testing
- fluticasone propionate/salmeterol, salmeterol xinafoate
- Where
- 91 sites in United States, Kenya and 2 more
- Volunteers
- 547 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of MRx-4DP0004 in Asthma
This is a multicentre, phase I/II, double-blind, placebo-controlled study of MRx-4DP0004 in participants taking long-term medication for asthma.
- Trial name
- NCT03851250
- Testing
- MRx-4DP0004
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- 4D pharma plc
Allergic Asthma
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis.
- Trial name
- X-PAND (NCT00813748)
- Testing
- Xolair
- Where
- 7 sites in United States
- Volunteers
- 118 people
- Sponsor
- Genentech, Inc.
Asthma
SABINA INTERNATIONAL
The aim of the study is to describe the prescribing pattern of the different types of medications which are used to treat asthma, across multiple countries.
- Trial name
- NCT03857178
- Where
- Argentina
- Volunteers
- 8,617 people
- Sponsor
- AstraZeneca
Asthma
Dose Finding Study for QAW039 in Asthma
This study aims to demonstrate a clinically significant improvement in Forced Expiratory Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled by Inhaled Corticosteroid (ICS) therapy.
- Trial name
- NCT01437735
- Testing
- QAW039, Montelukast
- Where
- 206 sites in United States, Argentina and 20 more
- Volunteers
- 1,043 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.